Evidence map›Paper›PMID 41383519›Full record

ArticleFrontiers in oncology2025

Right-side versus left-side hemihepatectomy for the treatment of Bismuth type IV perihilar cholangiocarcinoma: a comparative study.

Wencong Ma, Mingtai Hu, Zhihua Xie, Jianyang Ao, Peining Yan, Yao Huang, Jinghan Wang, Xiaoqing Jiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wencong Ma *Institute of Hepatobiliary and Pancreatic Surgery, Department of Hepatobiliary and Pancreatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Mingtai Hu *Institute of Hepatobiliary and Pancreatic Surgery, Department of Hepatobiliary and Pancreatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhihua Xie *Institute of Hepatobiliary and Pancreatic Surgery, Department of Hepatobiliary and Pancreatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jianyang AoInstitute of Hepatobiliary and Pancreatic Surgery, Department of Hepatobiliary and Pancreatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Peining YanDepartment of Biliary Tract Surgery I, The Third Hospital of Naval Medical University, Shanghai, China.
Yao HuangInstitute of Hepatobiliary and Pancreatic Surgery, Department of Hepatobiliary and Pancreatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Jinghan WangInstitute of Hepatobiliary and Pancreatic Surgery, Department of Hepatobiliary and Pancreatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.
Xiaoqing JiangInstitute of Hepatobiliary and Pancreatic Surgery, Department of Hepatobiliary and Pancreatic Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Radical surgical resection is the only potentially curative treatment for perihilar cholangiocarcinoma (PHC) patients. However, data on left-sided hemihepatectomy (LH) and right-sided hemihepatectomy (RH) outcomes for Bismuth-Corlette type IV PHC are scarce and controversial. This study aimed to explore surgical and long-term outcomes of LH and RH in these patients. Methods: Medical records of Bismuth type IV PHC patients who had liver resection from 2009 to 2018 were retrospectively analyzed. Surgical results and long-term survival were the primary outcomes, compared via one-to-one propensity score matching (PSM). Results: 218 Bismuth type IV PHC patients (146 LH, 72 RH) were analyzed. The RH group had a higher proportion of preoperative biliary drainage (p = 0.02) and more frequent portal vein embolization (p < 0.0001). R0 resection rate was 90.37% (197/218) with no significant LH-RH difference. Post-operative severe complication (grades 3-5) and 90-day mortality rates were comparable. Overall survival was similar (overall cohort: p=0.21; matched cohort: p=0.54). But in the overall cohort, R0-resected RH patients had marginally better survival (p = 0.064). Prognostic factors included carbohydrate antigen 19-9 (CA19-9), age, tumor vascular invasion, and severe post-operative complications. Conclusions: The postoperative morbidity and mortality rate was comparable between LH and RH for Bismuth type IV PHC. Although RH showed a favorable survival from the Kaplan-Meier survival curve, no significant difference was observed in overall survival after LH versus RH for the overall cohort and the matched cohort after PSM.

Indexed as

Bismuth type IVcholangiocarcinomahemihepatectomylocally advanced cholangiocarcinomaperihilar cholangiocarcinoma

Identifiers

PMID41383519
PMCPMC12689366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.